Nephros Non Current Liabilities Total vs Common Stock Shares Outstanding Analysis
| NEPH Stock | USD 1.56 0.02 1.30% |
Nephros financial indicator trend analysis is infinitely more than just investigating Nephros recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nephros is a good investment. Please check the relationship between Nephros Non Current Liabilities Total and its Common Stock Shares Outstanding accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.
Non Current Liabilities Total vs Common Stock Shares Outstanding
Non Current Liabilities Total vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nephros Non Current Liabilities Total account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Nephros' Non Current Liabilities Total and Common Stock Shares Outstanding is -0.46. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Nephros, assuming nothing else is changed. The correlation between historical values of Nephros' Non Current Liabilities Total and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Nephros are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Non Current Liabilities Total i.e., Nephros' Non Current Liabilities Total and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | -0.46 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Non Current Liabilities Total
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Nephros' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nephros current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.The Nephros' current Issuance Of Capital Stock is estimated to increase to about 6 M, while Selling General Administrative is projected to decrease to under 5.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.7M | 4.7M | 8.4M | 8.8M | Total Revenue | 10.4M | 10.0M | 14.2M | 14.9M |
Nephros fundamental ratios Correlations
Click cells to compare fundamentals
Nephros Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Nephros fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 11.6M | 18.5M | 17.7M | 11.0M | 11.9M | 7.5M | |
| Other Current Liab | 300K | 341K | 448K | 268K | 312K | 456.2K | |
| Total Current Liabilities | 2.4M | 1.3M | 2.4M | 1.4M | 2.1M | 1.6M | |
| Accounts Payable | 959K | 423K | 1.3M | 740K | 873K | 711.0K | |
| Cash | 4.2M | 8.2M | 7.0M | 3.6M | 4.3M | 2.7M | |
| Other Assets | 32K | 1.8M | 89K | 54K | 62.1K | 59.0K | |
| Common Stock Shares Outstanding | 7.5M | 9.1M | 10.0M | 10.3M | 10.4M | 10.9M | |
| Other Current Assets | 61K | 237K | 558K | 188K | 132K | 161.6K | |
| Total Liab | 3.9M | 2.9M | 2.9M | 2.1M | 3.5M | 2.9M | |
| Property Plant Equipment | 1.2M | 295K | 1.1M | 1.1M | 1.3M | 1.3M | |
| Short Long Term Debt Total | 2.5M | 2.2M | 1.1M | 1.1M | 1.8M | 1.7M | |
| Total Stockholder Equity | 4.7M | 12.5M | 11.7M | 5.6M | 8.4M | 8.8M | |
| Property Plant And Equipment Net | 1.2M | 1.3M | 1.1M | 1.1M | 2.0M | 2.1M | |
| Net Debt | (1.6M) | (6.1M) | (5.9M) | (2.5M) | (2.5M) | (2.3M) | |
| Retained Earnings | (127.3M) | (131.9M) | (135.7M) | (142.8M) | (144.4M) | (151.6M) | |
| Non Current Assets Total | 3.3M | 3.4M | 4.0M | 2.7M | 3.5M | 1.8M | |
| Non Currrent Assets Other | 18K | 32K | 89K | 54K | 86K | 81.7K | |
| Cash And Short Term Investments | 4.2M | 8.2M | 7.0M | 3.6M | 4.3M | 3.7M | |
| Liabilities And Stockholders Equity | 11.6M | 18.5M | 17.7M | 11.0M | 11.9M | 7.8M | |
| Non Current Liabilities Total | 1.5M | 1.6M | 511K | 706K | 1.4M | 2.0M | |
| Other Stockholder Equity | 131.9M | 144.3M | 147.3M | 148.4M | 152.8M | 109.1M | |
| Property Plant And Equipment Gross | 1.2M | 1.3M | 1.1M | 1.1M | 2.9M | 3.1M | |
| Total Current Assets | 8.3M | 15.2M | 13.6M | 8.3M | 8.4M | 6.1M | |
| Short Term Debt | 1.2M | 1.0M | 561K | 387K | 892K | 744.8K | |
| Inventory | 2.6M | 5.3M | 4.8M | 3.2M | 2.5M | 1.4M | |
| Net Receivables | 1.0M | 1.4M | 1.6M | 1.3M | 1.5M | 806.7K | |
| Long Term Debt | 623K | 846K | 95K | 1K | 900.0 | 855.0 | |
| Intangible Assets | 1.4M | 1.2M | 2.1M | 825K | 652K | 1.1M | |
| Net Tangible Assets | 2.6M | 10.6M | 8.9M | 4.0M | 4.6M | 2.7M | |
| Capital Surpluse | 122.9M | 127.8M | 131.9M | 144.3M | 165.9M | 134.3M |
Currently Active Assets on Macroaxis
When determining whether Nephros offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nephros' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nephros Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nephros Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nephros. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Household Appliances space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share 1.313 | Quarterly Revenue Growth (0.08) | Return On Assets (0.08) | Return On Equity (0.16) |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.